摘要
肥胖症及其相关并发症的流行已成为公共卫生领域的重大挑战,这一难题也推动着减重药物的快速发展。近年来,基于多肽激素或基因表达通路的新型减重药物不断涌现,如胰高糖素样肽-1(GLP-1)受体激动剂、葡萄糖依赖性促胰岛素多肽(GIP)/GLP-1双受体激动剂、胰淀粉样多肽类似物以及黑皮质素-4受体(MC4R)激动剂等,为单纯性肥胖、代谢相关性肥胖及遗传性肥胖患者提供了更多选择。值得注意的是,新型药物的长期用药安全性、停药后的体重管理以及个体化治疗方案优化等问题仍需更多的研究进行验证。
The obesity and its related complications has become a major challenge in public health,driv-ing the rapid development of weight management medications.In recent years,novel weight-loss drugs based on peptide hormones or gene expression pathways-such as glucagon-like peptide-1(GLP-1)receptor agonists,glucose-dependent insulinotropic polypeptide(GIP)/GLP-1 dual receptor agonists,amylin analogs,and melanocortin-4 re-ceptor(MC4R)agonists-have emerged,providing breakthrough options for patients with simple obesity,metabolic-related obesity,and genetic obesity.Notably,further research is still needed to validate the long-term safety of these new drugs,weight management after discontinuation,and the optimization of individualized treatment regi-mens.
作者
接恒博
李若涵
都丽萍
梅丹
Jie Hengbo;Li Ruohan;Du Liping;Mei Dan(Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)
出处
《中国药物与临床》
2025年第9期566-572,共7页
Chinese Remedies & Clinics
基金
中央高水平医院临床科研专项(2022-PUMCH-A-199)
中国医学科学院中央级公益性科研院所基本科研业务费项目(2022-RW350-01)。
关键词
肥胖症
减肥药
减肥计划
胰高糖素样肽-1
Obesity
Anti-obesity agents
Weight reduction programs
Glucagon-like peptide-1
